Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

ABSTRACT: This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR (ECD-EGFR).

DISEASE(S): Metastatic Colorectal Cancer,Cáncer Colorrectal Metastásico Y Resistencia Adquirida A Anticuerpos Monoclonales Anti-egfr Y Con Mutación Documentada Del Dominio Extracelular Del Egfr (ecd-egfr),Metastatic Colorectal Cancer And Acquired Resistance To Anti-egfr Monoclonal Antibodies And Documented Mutation Of Extra Cellular Doman Of Egfr,Colorectal Neoplasms

PROVIDER: 2229961 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR